Dicot Pharma Dicot Pharma
På svenska

We develop the next generation potency drug.

To enhance quality of life for men and couples worldwide.

Dicot Pharma Raises SEK 231 Million

Dicot Pharma’s rights issue was oversubscribed and subscribed to approximately 134 percent. Through the rights issue and a directed share issue, the company will receive a total of approximately SEK 231 million before issue-related costs, to support the continued development of LIB-01.

Press Releases

Dicot Pharma’s World in Numbers

Approx.
billion SEK/year
The global sales of erectile dysfunction treatments.
Approx.
percent
The proportion of men with erectile dysfunction who discontinue treatment with current medications.
At least
days
LIB-01's duration according to phase 2a-study.
percent
Increase in number of shareholders in one year.

The Annual Report 2025 is now available.

Follow our positive development journey throughout the year. Explore a comparison between LIB-01 and current treatments, along with interviews with Chair of the Board Eva Sjökvist Saers and sexual medicine expert Dr. Harin Padma-Nathan.

Financial calendar and events

Dicot Pharma highlighted in Oppenheimer’s report

The global investment bank Oppenheimer has published an equity research report where Dicot Pharma and LIB-01 for the treatment of erectile dysfunction are singled out as being of particular interest. The report is part of Oppenheimer’s focus on longevity as the next major trend for biotech investors and highlights a clear link between erectile dysfunction and healthy aging.